Gut microbiota mediates the response to anti-PD-1 and programmed death ligand 1 (PD-L1) immunotherapies, which blocks the interaction between PD-1 on T cells and PD-L1 on tumor cells or antigen-presenting cells (Lu et al, 2022). Here, PDCD1 is linked to neoplasm.